Table 5.
Associations between variables collected at patient's last visit, HAQ and JADI
| Variables | HAQ |
JADI-A |
JADI-E |
|||
|---|---|---|---|---|---|---|
| β (95% CI) | p Value | β (95% CI) | p Value | β (95% CI) | p Value | |
| ILAR category* | ||||||
| E. oligoarticular | 0.3 (0.1 to 0.5) | 0.006† | 6.8 (−1.2 to 14.7) | 0.094 | 0.5 (−0.5 to 1.6) | 0.335 |
| RF+ polyarticular | 0.5 (0.3 to 0.8) | <0.001† | 17.5 (8.1 to 16.8) | <0.001† | 0.5 (−0.8 to 1.7) | 0.484 |
| RF-poly articular | 0.4 (0.1 to 0.6) | 0.001† | 8.8 (1.6 to 16.0) | 0.018† | 1.1 (0.2 to 2.1) | 0.022† |
| Systemic | 0.2 (−0.1 to 0.4) | 0.193 | 12.2 (2.8 to 21.5) | 0.011† | 1.0 (−0.3 to 2.3) | 0.123 |
| ERA | 0.2 (−0.0 to 0.4) | 0.077 | 4.7 (−2.6 to 12.0) | 0.208 | 0.4 (−0.5 to 1.4) | 0.363 |
| PsA | 0.1 (−0.2 to 0.5) | 0.480 | −0.8 (−21.0 to 19.3) | 0.934 | −0.2 (−2.6 to 2.2) | 0.860 |
| Undiff arthritis | 0.4 (−0.1 to 1.0) | 0.130 | NA | NA | NA | NA |
| Adult rheumatic diseaseठ| ||||||
| PsA | 0.2 (−0.1 to 0.5) | 0.194 | 1.5 (−13.2 to 16.1) | 0.844 | 0.1 (−1.7 to 1.9) | 0.913 |
| RA | 0.5 (0.3 to 0.7) | <0.001† | 4.4 (−3.6 to 12.4) | 0.275 | 0.5 (−0.6 to 1.6) | 0.358 |
| ASD—systemic persistent | −0.6 (−1.0 to −0.2) | 0.003† | NA | NA | −0.8 (−3.1 to 1.4) | 0.448 |
| ASD—polyarticular predominant | NA | NA | 17.2 (2.1 to 32.3) | 0.026† | NA | NA |
| USpA | 0.0 (−0.3 to 0.3) | 0.965 | −1.8 (−12.2 to 8.5) | 0.729 | −0.2 (−1.6 to 1.2) | 0.752 |
| AS | 0.3 (0.4 to 0.6) | 0.024† | −0.2 (−10.2 to 9.8) | 0.971 | 0.5 (−0.9 to 1.8) | 0.466 |
| EA | −0.0 (−0.5 to 0.4) | 0.882 | −3.6 (−19.8 to 12.6) | 0.663 | −0.4 (−2.9 to 2.1) | 0.752 |
| Age at disease onset‡ | −0.0 (−0.0 to 0.0) | 0.767 | −0.7 (−1.3 to −0.2) | 0.010† | −0.1 (−0.1 to 0.0) | 0.095 |
| Disease duration‡ | 0.0 (0.0 to 0.0) | <0.001† | 0.3 (0.1 to 0.5) | 0.001† | 0.0 (0.0 to 0.1) | 0.001† |
| Delay in diagnosis‡ | 0.0 (0.0 to 0.0) | <0.001† | −0.0 (−0.3 to 0.2) | 0.787 | −0.0 (−0.1 to 0.0) | 0.157 |
| ANA‡ | 0.0 (−0.1 to 0.2) | 0.732 | 6.0 (−1.2 to 13.3) | 0.102 | 1.1 (0.1 to 2.1) | 0.033† |
| RF‡ | 0.1 (−0.2 to 0.4) | 0.606 | −1.5 (−11.9 to 8.8) | 0.772 | −0.2 (−1.8 to 1.3) | 0.784 |
| B27‡ | 0.0 (−0.2 to 0.3) | 0.748 | −6.6 (−15.2 to 2.0) | 0.132 | −0.5 (−1.5 to 0.5) | 0.286 |
| ACPA‡ | 0.2 (−0.3 to 0.7) | 0.398 | −3.5 (−31.9 to 24.9) | 0.804 | 4.1×10−15 (−6.1 to 6.1) | ≈1 |
| Professional activityঠ| ||||||
| Unemployed | 0.0 (−0.3 to 0.3) | 0.904 | 1.1 (−7.8 to 10.0) | 0.811 | 1.0 (−0.5 to 2.4) | 0.178 |
| Retired due to JIA disability | 1.0 (0.7 to 1.3) | <0.001† | 29.1 (19.9 to 38.3) | <0.001† | 1.4 (0.2 to 2.6) | 0.028† |
| Years of education‡ | −0.0 (−0.1 to −0.0) | 0.001† | −0.1 (−0.9 to 0.7) | 0.795 | −0.1 (−0.2 to 0.1) | 0.367 |
| HAQ Score‡ | 12.5 (10.2 to 14.9) | <0.001† | 1.1 (0.7 to 1.4) | <0.001† | ||
| Duration of corticosteroid therapy‡ | 0.0 (0.0 to 0.0) | <0.001† | 0.0 (0.0 to 0.0) | 0.020† | 0.0 (0.0 to 0.0) | <0.001† |
| Exposure to corticosteroids‡ | 0.3 (0.2 to 0.5) | <0.001† | 4.5 (−1.1 to 10.2) | 0.112 | 1.2 (0.5 to 1.9) | 0.001† |
| Exposure to biological DMARDs‡ | 0.2 (0.0 to 0.3) | 0.014† | 6.9 (1.3 to 12.5) | 0.016† | 0.6 (−0.1 to 1.3) | 0.080 |
| Exposure to synthetic DMARDs‡ | −0.1 (−0.3 to 0.1) | 0.394 | −1.2 (−7.4 to 5.0) | 0.699 | −0.1 (−0.9 to 0.8) | 0.864 |
†p Value <0.05.
*Compared to persistent oligoarticular.
‡Adjusted for ILAR category.
§Compared to non-classifiable.
¶Compared to employed.
ACPA, anticitrullinated protein antibodies; ANAs, antinuclear antibodies; AS, ankylosing spondylitis; ASD, adult Still disease; DMARDs, disease-modifying antirheumatic drugs; E. oligoarthritis, extended oligoarthritis; EA, enteropathic arthritis; ERA, enthesitis-related arthritis; HAQ, Health Assessment Questionnaire; ILAR, International League of Associations for Rheumatology; JADI, Juvenile Arthritis Damage Index; JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RF, rheumatoid factor; RF+ polyarthritis, rheumatoid factor negative polyarthritis; RF+ polyarthritis, rheumatoid factor positive polyarthritis; SoJIA, systemic-onset juvenile idiopathic arthritis; Undif arthritis, undifferentiated arthritis; USpA, undifferentiated spondyloarthritis.